TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05915975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Care Coordinated with Medical Care Intervention
Description: Participants will be meeting with a behavioral health provider during their clinic visit. Subsequent visits can be held either via telehealth or in-person. Participants should expect weekly visits during the first two months and less frequent visits (biweekly or monthly) for the last two months. Some sessions that are provided via telehealth might be video recorded and later reviewed to ensure that the program is being delivered as intended.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Care Not Coordinated with Medical Care Intervention
Description: Participants will meet with a study team member during their in-person visit and will receive a list of clinics that are panelled with their insurance. The participants will be responsible for calling the clinics to set up their appointments. Services might be provided in person or via telehealth based on the participant's preference and the clinics' availability.
Study: NCT05500196

Intervention type: DEVICE
Intervention: Per Oral Endoscopy Myotomy (POEM)
Description: POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.

Intervention type: DEVICE
Intervention: Per Oral Endoscopy Myotomy (POEM)
Description: POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to reach the inner circular muscle bundles of the LES to perform myotomy, while preserving the outer longitudinal muscle bundles. The result is decreased resting pressure of the LES, facilitating the passage of ingested material.
Study: NCT05486793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Description: 5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Description: 5 individual sessions that cover psychoeducation about PTSD, the rationale for exposure treatment, and directing patients to write in session for 30 minutes about their traumatic experience using scripted instructions. Each session includes unique writing instructions. Earlier sessions focus on describing the details of a traumatic stressor linked to their symptoms, with particular attention to felt emotions and thoughts. Later writing sessions focus on writing about the meaning of the traumatic event and how the event has changed their life and how they relate to other people. After writing, therapists spend \~10 minutes processing the patient's experience with the writing. WET does not include between session assignments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emotion Focused Supportive Therapy (EFST)
Description: 5 individual sessions where patients choose what problems to discuss in each session. Therapists validate and clarify patients' emotions and engage in problem solving during sessions.
Study: NCT04769336

Intervention type: DEVICE
Intervention: Central Lab based CBC
Description: lab samples will be sent to the central lab for CBC analysis
Study: NCT06396767

Intervention type: DIAGNOSTIC_TEST
Intervention: DIA measured via Ultrasonography
Description: Ultrasound will be used to measure Diaphragmatic Inspiratory Amplitude (DIA) of patients before and after elective cardiac surgery to determine if there is a correlation between changes in DIA and postoperative pulmonary complications.
Study: NCT04769336

Intervention type: DEVICE
Intervention: Point of Care CBC
Description: lab samples will be analyzed at point of care
Study: NCT04767776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: rivaroxaban 40 mg/day (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: rivaroxaban 40 mg/day (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: rivaroxaban 40 mg/day (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: rivaroxaban 40 mg/day (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: Activated charcoal 2 hours after rivaroxaban administration (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: Activated charcoal 2 hours after rivaroxaban administration (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: Activated charcoal 2 hours after rivaroxaban administration (1 day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: Activated charcoal 2 hours after rivaroxaban administration (1 day).
Study: NCT05590104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic CS scar defect repair
Description: Dilatation of the cervix till 7 mm. Introduce the resctoscope through the cervix. The surgical correction of the isthmocele is done by resection of the inferior and superior edges or just the inferior edge of the defect with a resectoscopic loop, using pure cutting current, until reaching the muscular layer. Coagulation of fragile vessels at the base or even entire niche. At the end of procedure, flow and pressure of distending medium can be reduced to ensure adequate haemostasis.
Study: NCT04828850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound transbronchial needle aspiration lymph node staging
Description: EBUS-TBNA in clinical N0 NSCLC patients
Study: NCT04935372

Intervention type: OTHER
Intervention: Observational
Description: Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described.
Study: NCT04746313

Intervention type: BIOLOGICAL
Intervention: blood test
Description: * to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin

Intervention type: BIOLOGICAL
Intervention: blood test
Description: * to analysis prolactin in healthy subjects and scleroderma patients~* then to analysis in only scleroderma patients: thyroid-stimulating hormone (TSH), thyroxine (T4), luteinizing hormone (LH), oestradiol, follicle-stimulating hormone (FSH), BAFF (B-cell activating factor), IL-6 (interleukin 6) and endoglin
Study: NCT05263011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado
Description: 1 avocado as evening snack

Intervention type: OTHER
Group type: OTHER
Intervention: low fat yogurt
Description: 1 serving of low fat yogurt matching calories of 1 avocado

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low fat yogurt + fiber +fat
Description: low fat yogurt mixed with ultra processed olive oil + fiber supplement, equivalent to fat and fiber content in 1 avocado
Study: NCT04481945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bioceramic sealer
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioceramic sealer
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bioceramic sealer
Description: pre-mixed bioceramic obturation material. It is dispensed using a syringe in cases of root canal obturation and with either a syringe or as a putty when doing root repair and retrograde fillings.
Study: NCT02866461

Intervention type: OTHER
Intervention: No treatment
Description: Observation
Study: NCT05298228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam bolus does administration
Description: The beginning dose of remimazolam is 0.3 mg/kg, and when LMA insertion is successful, the dose will be decreased by 0.05 mg/kg in the next patient. When LMA insertion is unsuccessful (failed), the dose will be increased by 0.05 mg/kg in the next patient.
Study: NCT05628987

Intervention type: OTHER
Intervention: no intervention
Description: Observational studies, no intervention

Intervention type: OTHER
Intervention: no intervention
Description: Observational studies, no intervention

Intervention type: OTHER
Intervention: no intervention
Description: Observational studies, no intervention

Intervention type: OTHER
Intervention: no intervention
Description: Observational studies, no intervention
Study: NCT05236764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: Peripheral blood stem cells from closely matched unrelated donors will be processed using the CliniMACS device to remove TCRalpha/beta (alpha beta+) T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
Study: NCT04873245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Behavioral Program
Description: Participants randomized to this group will receive intensive behavioral therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide and Behavioral Program
Description: Participants randomized to this group will receive semaglutide and behavioral therapy.
Study: NCT06592924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (BAY 1841788)
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darolutamide (BAY 1841788)
Description: Assigned prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Assigned at enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Physician's choice. Assigned prior to enrollment
Study: NCT05628987

Intervention type: OTHER
Intervention: no intervention
Description: Observational studies, no intervention
Study: NCT06592924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Physician's choice. Assigned prior to enrollment
Study: NCT06594796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined lifestyle intervention and LBP care (physiotherapy, exercise therapy)
Description: One of five recognized combined lifestyle interventions (BeweegKuur, CooL, SSIB, SLIMMER, X-Fittt) integrated with LBP care.
Study: NCT06586216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Experimental

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07817883
Description: Experimental
Study: NCT06592833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin, 25mg, given once orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin
Description: Psilocybin, 25mg, given once orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimavanserin
Description: Pimavanserin, 34mg, given once orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study: NCT04592211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib+pembrolizumab+paclitaxel
Description: olaparib, 100\~200mg, PO, bid, continuous Pembrolizumab 200mg, IV, q 3 weeks Paclitaxel 80mg/m2 IV, Q weekly
Study: NCT06657378

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06659341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3498264
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3498264
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3498264
Description: Oral
Study: NCT06661122

Intervention type: DRUG
Intervention: Darolutamide (BAY1841788) + docetaxel + ADT
Description: Follow clinical practice/administration. ADT=androgen deprivation therapy.
Study: NCT06655142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONCObind (Onco-Seraph) 100 Filter
Description: The ONCObind Microbind® Affinity Blood Filter ( ONCObind) manufactured by ExThera Medical Corporation in Martinez, CA. The ONCObind filter has been designed and manufactured to reduce residual risks as much as possible to ensure safe usage. Literature search results concluded that heparin-coated medical devices are safe and decrease platelet adhesion without affecting the adsorption of major adhesive proteins. Literature search yielded over 60 publications and 500 treated patients with Seraph platform technology for pathogen removals without and significant safety concern. The achieved results from the above-mentioned testing and studies support the performance and safety of ONCObind consistent with the intended use. ExThera Medical concludes that the known and potential benefits of ONCObind, when used to treat patients with PDAC, outweigh the known and potential risks when used according to the intended use.

Intervention type: OTHER
Group type: OTHER
Intervention: Matched Controls
Description: Study patients will be assigned to receive procedure with the investigational device (ONCObind) and will be matched with 60 site specific controls, 30 PDAC and 30 CRC.
Study: NCT05472818

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]APP311
Description: For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [11C]APP311
Description: For each \[11C\]APP311 (UCB-J) PET scan, up to 20 mCi of \[11C\]APP311 (UCB-J) will be administered by infusion pump. All participants will receive at least two \[11C\]APP311 (UCB-J) PET scans approx. 4 weeks days apart. Approximately 8 CUD participants will be asked to return for a third \[11C\]APP311 (UCB-J) PET scan after an additional 4 weeks following their second scan.
Study: NCT06602219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4100511
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT06606847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)
Study: NCT06601686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation (TES)
Description: TES uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial electrical stimulation with temporal interference (TES-TI)
Description: TES-TI uses specific electrode arrangement patterns to selectively stimulate the brain. Participants will wear an hdEEG (high density electroencephalography) cap which will allow intermittent periods of stimulation from TES-TI.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Description: TES-TI sham includes receiving stimulation from all electrodes at the same frequency. Sham TES will include administration of transcranial random noise stimulation (tRNS), random oscillating current.
Study: NCT03555968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 0
Description: THC dose = 0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 0
Description: THC dose = 0mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THC 0
Description: THC dose = 0mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5
Description: THC dose = 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5
Description: THC dose = 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5
Description: THC dose = 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5
Description: THC dose = 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5
Description: THC dose = 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 10
Description: THC dose = 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 10
Description: THC dose = 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 10
Description: THC dose = 10mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: BAC 0
Description: Blood alcohol concentration = .000%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC 0
Description: Blood alcohol concentration = .000%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC 0
Description: Blood alcohol concentration = .000%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .025
Description: Blood alcohol concentration = .025%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .025
Description: Blood alcohol concentration = .025%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .025
Description: Blood alcohol concentration = .025%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .025
Description: Blood alcohol concentration = .025%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .049
Description: Blood alcohol concentration = .049%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .049
Description: Blood alcohol concentration = .049%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .049
Description: Blood alcohol concentration = .049%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAC .049
Description: Blood alcohol concentration = .049%
Study: NCT06186024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge
Description: Stent implantation
Study: NCT06315686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: The efficacy of Furmonertinib combined with OMMAYA lateral ventricle chemotherapy (pemetrexed) was evaluated once a week during the treatment phase. After the brain lesions were evaluated as CR, the drug holiday study phase was added. During the study period, the patients were followed up once a week until the investigators deemed the subjects unfit to continue to participate in the study or the efficacy was evaluated as disease progression (PD).
Study: NCT06037512

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: subject
Description: blood glucose measurement by subject

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: reference
Description: blood glucose measurement with reference
Study: NCT06039969

Intervention type: OTHER
Description: This is an obvertional study and there is no intervention
Study: NCT04737759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taking Care of Us
Description: A social-behavioral intervention that is targeted at the couple living with heart failure and delivered via Zoom.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SUPPORT
Description: SUPPORT is an educational counseling intervention that is targeted at the couple living with heart failure and delivered by Zoom.
Study: NCT04630210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day oral until surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg/day oral until surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 840 mg intravenous (IV) single-dose 14 days (+/- 4 days) before surgery